Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: The Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS)

Atherosclerosis

Volumn 215, Issue 2, 2011, Pages 440-445

  Östling, Gerd ^a   Gonçalves, Isabel ^a   Wikstrand, John ^b   Berglund, Göran ^a   Nilsson, Jan ^a   Hedblad, Bo ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Blocker; Echogenicity; Plaque; Ultrasound

Indexed keywords

CHOLESTEROL; FLUINDOSTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; METOPROLOL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD VESSEL PARAMETERS; BODY MASS; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FACTORIAL DESIGN; FOLLOW UP; GLUCOSE BLOOD LEVEL; GRAY SCALE ECHOGRAPHY; HEART RATE; HUMAN; INTIMA MEDIA THICKNESS; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADRENERGIC BETA-ANTAGONISTS; AGED; CAROTID ARTERY DISEASES; DOUBLE-BLIND METHOD; FATTY ACIDS, MONOUNSATURATED; HUMANS; INDOLES; METOPROLOL; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC;

EID: 79953062298     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.12.031     Document Type: Article

References (30)

1. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115:459-467.
2. Bots M.L., Visseren F.L., Evans G.W., et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007, 370:153-160.
3. Hedblad B., Wikstrand J., Janzon L., Wedel H., Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001, 103:1721-1726.
4. Hedblad B., Zambanini A., Nilsson P., Janzon L., Berglund G. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. J Intern Med 2007, 261:293-305.
5. Salonen R., Nyyssonen K., Porkkala E., et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995, 92:1758-1764.
6. Gronholdt M.L., Nordestgaard B.G., Schroeder T.V., Vorstrup S., Sillesen H. Ultrasonic echolucent carotid plaques predict future strokes. Circulation 2001, 104:68-73.
7. Mathiesen E.B., Bonaa K.H., Joakimsen O. Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis: the tromso study. Circulation 2001, 103:2171-2175.
8. Gronholdt M.L., Wiebe B.M., Laursen H., et al. Lipid-rich carotid artery plaques appear echolucent on ultrasound B-mode images and may be associated with intraplaque haemorrhage. Eur J Vasc Endovasc Surg 1997, 14:439-445.
9. Gronholdt M.L., Nordestgaard B.G., Bentzon J., et al. Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels. J Vasc Surg 2002, 35:137-145.
10. Goncalves I., Lindholm M.W., Pedro L.M., et al. Elastin and calcium rather than collagen or lipid content are associated with echogenicity of human carotid plaques. Stroke 2004, 35:2795-2800.
11. Wiklund O., Hulthe J., Wikstrand J., et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002, 33:572-577.
12. Smilde T.J., van Wissen S., Wollersheim H., et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001, 357:577-581.
13. Anderssen S.A., Hjelstuen A.K., Hjermann I., Bjerkan K., Holme I. Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis 2005, 178:387-397.
14. Crouse J.R., Raichlen J.S., Riley W.A., et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. J Am Med Assoc 2007, 297:1344-1353.
15. Kadoglou N.P., Gerasimidis T., Moumtzouoglou A., et al. Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis. Eur J Vasc Endovasc Surg 2008, 35:661-668.
16. Schartl M., Bocksch W., Koschyk D.H., et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001, 104:387-392.
17. Watanabe K., Sugiyama S., Kugiyama K., et al. Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesterolemic patients with coronary artery disease. J Am Coll Cardiol 2005, 46:2022-2030.
18. Liang C., Xiaonan L., Xiaojun C., et al. Effect of metoprolol on vulnerable plaque in rabbits by changing shear stress around plaque and reducing inflammation. Eur J Pharmacol 2009, 613:79-85.
19. Berglund G., Elmstahl S., Janzon L., Larsson S.A. The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 1993, 233:45-51.
20. Rosvall M., Janzon L., Berglund G., Engstrom G., Hedblad B. Incident coronary events and case fatality in relation to common carotid intima-media thickness. J Intern Med 2005, 257:430-437.
21. Wendelhag I., Wiklund O., Wikstrand J. Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia. Ultrasonographic assessment of intima-media thickness and plaque occurrence. Arterioscler Thromb 1993, 13:1404-1411.
22. Persson J., Stavenow L., Wikstrand J., et al. Noninvasive quantification of atherosclerotic lesions. Reproducibility of ultrasonographic measurement of arterial wall thickness and plaque size. Arterioscler Thromb 1992, 12:261-266.
23. Wendelhag I., Liang Q., Gustavsson T., Wikstrand J. A new automated computerized analyzing system simplifies readings and reduces the variability in ultrasound measurement of intima-media thickness. Stroke 1997, 28:2195-2200.
24. Elatrozy T., Nicolaides A., Tegos T., et al. The effect of B-mode ultrasonic image standardisation on the echodensity of symptomatic and asymptomatic carotid bifurcation plaques. Int Angiol 1998, 17:179-186.
25. Ablad B., Bjorkman J.A., Gustafsson D., et al. The role of sympathetic activity in atherogenesis: effects of beta-blockade. Am Heart J 1988, 116:322-327.
26. Nielsen L.B. Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis. Atherosclerosis 1996, 123:1-15.
27. Kaplan J.R., Manuck S.B., Adams M.R., Clarkson T.B. The effects of beta-adrenergic blocking agents on atherosclerosis and its complications. Eur Heart J 1987, 8:928-944.
28. Prabhu S.D., Chandrasekar B., Murray D.R., Freeman G.L. beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000, 101:2103-2109.
29. Funovic P., Korda M., Kubant R., et al. Effect of beta-blockers on endothelial function during biological aging: a nanotechnological approach. J Cardiovasc Pharmacol 2008, 51:208-215.
30. Crisby M., Nordin-Fredriksson G., Shah P.K., et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103:926-933.